Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Current Assets: 2019-2025

Historic Current Assets for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Legend Biotech's Current Assets fell 8.00% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 8.00%. This contributed to the annual value of $1.3 billion for FY2024, which is 14.28% down from last year.
  • Per Legend Biotech's latest filing, its Current Assets stood at $1.2 billion for Q3 2025, which was down 0.63% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Current Assets ranged from a high of $1.6 billion in Q2 2023 and a low of $475,074 during Q1 2021.
  • Its 3-year average for Current Assets is $1.3 billion, with a median of $1.4 billion in 2024.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 181,849.97% in 2022, then decreased by 14.28% in 2024.
  • Over the past 5 years, Legend Biotech's Current Assets (Quarterly) stood at $949.9 million in 2021, then rose by 15.72% to $1.1 billion in 2022, then soared by 36.27% to $1.5 billion in 2023, then decreased by 14.28% to $1.3 billion in 2024, then decreased by 8.00% to $1.2 billion in 2025.
  • Its Current Assets was $1.2 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.2 billion in Q1 2025.